- $98.13m
- $152.41m
- $78.23m
Brief: Optinose Announces Proposed Public Offering Of Common Stock And Warrants
OptiNose Inc reports results for the quarter ended in September - Earnings Summary
Brief: Optinose Reports Q3 2022 Financial Results
OptiNose Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Optinose Says On Sept 20 Entered Into Amendment No. 2 To Manufacturing Services Agreement For Sub-Assembly With Advance Mold & Manufacturing
OptiNose Inc reports results for the quarter ended in June - Earnings Summary
Brief: OptiNose Reports Second Quarter 2022 Financial Results, Operational Updates
OptiNose Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Optinose Announces XHANCE Significantly Reduced Incidence Of Exacerbations For Patients With Chronic Sinusitis In Landmark Reopen Program
OptiNose up after additional chronic sinus treatment trial data
U.S. STOCKS ON THE MOVE-Choice Hotels International Inc, Campbell Soup, Day One Biopharmaceuticals
U.S. STOCKS ON THE MOVE-IMAX Corp, Volta, Ekso Bionics Holdings
U.S. STOCKS ON THE MOVE-Electric Last Mile Solutions, bluebird bio, Duke Realty Corp
OptiNose rises after sinusitis therapy succeeds in second study
Brief: Optinose Announces Positive Top-Line Results Of Reopen2, Its Second Phase 3 Clinical Trial Of Xhance For Treatment Of Chronic Sinusitis
Brief: Optinose Announces Departure Of Chief Financial Officer
OptiNose falls on lower-than-expected lead drug revenue in Q1
OptiNose Inc reports results for the quarter ended in March - Earnings Summary
Brief: Optinose Reports First Quarter 2022 Financial Results And Operational Updates